Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have been given an average recommendation of “Moderate Buy” by the eight research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $7.50.

Several equities analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sana Biotechnology in a report on Saturday, September 27th. Morgan Stanley assumed coverage on Sana Biotechnology in a research note on Thursday, July 3rd. They set an “overweight” rating and a $12.00 price objective on the stock. JMP Securities reissued a “market outperform” rating and issued a $5.00 target price on shares of Sana Biotechnology in a research note on Tuesday, June 24th. Finally, Wedbush started coverage on Sana Biotechnology in a report on Wednesday, September 24th. They set an “outperform” rating and a $5.00 target price for the company.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of SANA. Ameriprise Financial Inc. purchased a new stake in Sana Biotechnology in the 4th quarter worth approximately $29,000. Pallas Capital Advisors LLC purchased a new stake in Sana Biotechnology in the first quarter worth $29,000. Nisa Investment Advisors LLC boosted its holdings in Sana Biotechnology by 673.8% in the second quarter. Nisa Investment Advisors LLC now owns 10,911 shares of the company’s stock valued at $30,000 after acquiring an additional 9,501 shares in the last quarter. Hoey Investments Inc. purchased a new position in Sana Biotechnology during the 2nd quarter valued at $33,000. Finally, BNP Paribas Financial Markets bought a new position in Sana Biotechnology in the 4th quarter worth $34,000. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Trading Up 5.1%

Shares of NASDAQ SANA opened at $4.16 on Tuesday. The stock has a market cap of $989.29 million, a price-to-earnings ratio of -3.92 and a beta of 1.91. Sana Biotechnology has a 1-year low of $1.26 and a 1-year high of $7.30. The stock’s 50-day moving average is $3.42 and its 200 day moving average is $2.81.

Sana Biotechnology (NASDAQ:SANA) last issued its earnings results on Monday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.04. On average, analysts forecast that Sana Biotechnology will post -1.16 EPS for the current fiscal year.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.